FDA Approves Opdivo With Yervoy for Unresectable or Metastatic Hepatocellular Carcinoma

The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for ...

APRIL 23, 2025

Expert Picks From The Liver Meeting 2024

Ashwani Singal, MD, MS, discusses abstracts on managing variceal bleeding, hepatocellular carcinoma and more.

APRIL 14, 2025

Evolving the Treatment Paradigm in Second-Line Primary Biliary Cholangitis With IQIRVO (elafibranor): A First-in-Class PPAR Agonist

This Special Report discusses considerations for monitoring and treating patients with primary biliary cholangitis ...

APRIL 1, 2025

FDA Approves Opdivo Qvantig for Subcutaneous Injection

The FDA approved nivolumab plus hyaluronidase (Opdivo Qvantig, Bristol Myers Squibb) for an array of GI cancers.

JANUARY 8, 2025

Expert Picks From EASL 2024

Ashwani K. Singal, MD, MS, highlights four abstracts from EASL Congress 2024.

OCTOBER 30, 2024

New ACG Guideline on Managing Focal Liver Lesions

The American College of Gastroenterology recently released a new clinical guideline on focal liver lesions.

OCTOBER 17, 2024

Noninvasive Tools Can Predict Liver-Related Events

A combination of a liver stiffness measurement and clinical parameters may allow prediction of liver-related ...

AUGUST 26, 2024

Expert Picks From AASLD 2023

In this installment of Expert Picks, Ashwani Singal, MD, MS, discusses five of his favorite abstracts from The ...

FEBRUARY 14, 2024

First-Degree Relatives of MASLD Patients Are at Higher Risk for HCC

Some relatives of people with metabolic dysfunction–associated steatotic liver disease are at higher risk for ...

DECEMBER 24, 2023

Improved Biomarkers Can Aid HCC Diagnosis, Predict Disease Course

Researchers in the Netherlands and Latin America have identified a new score using existing serum biomarkers to ...

DECEMBER 23, 2023

Albumin-Bilirubin Grade Proposed as Prognostic Tool in Hepatocellular Carcinoma

Results of a retrospective study suggest that the albumin-bilirubin grade might be more useful in classifying ...

OCTOBER 30, 2023

Novel First-Line Therapy’s OS Benefit for Liver Cancer Persists

Long-term overall survival in hepatocellular carcinoma with tremelimumab plus durvalumab treatment is durable, ...

OCTOBER 27, 2023